CVS Opioid Lawsuit: DOJ Claims, Defenses, and Settlements

The CVS opioid lawsuit filed by the U.S. Department of Justice in December 2024 accuses the pharmacy chain of knowingly filling thousands of unlawful opioid prescriptions between October 2013 and the present, then billing federal healthcare programs like TRICARE for them. The case, pending in the U.S. District Court for the District of Rhode Island, is separate from the $4.9 billion settlement CVS reached with state and local governments in 2022. It is still in early motion practice, with no trial date set.¹

What the DOJ Is Alleging

The government’s 97-page complaint covers conduct across CVS’s network of more than 9,000 pharmacies. It alleges CVS routinely filled prescriptions that lacked any legitimate medical purpose, including prescriptions for dangerously excessive quantities of opioids, early refills, and “trinity” combinations of an opioid, a benzodiazepine, and a muscle relaxant — a mix known for its potentially fatal sedative effects.² The DOJ also says CVS filled prescriptions from “pill mill” doctors operating outside legitimate medical practice.¹

The complaint describes ten patients who died of overdoses shortly after filling prescriptions at CVS.³ One was a Virginia patient who in 2018 received overlapping high-dose prescriptions for oxycodone and morphine combined with alprazolam, a pairing CVS internally labeled a “double threat.” The patient died of a mixed drug overdose four days after filling the final prescription. The prescribing doctor later pleaded guilty to writing those prescriptions unlawfully and admitted they had no legitimate medical purpose.⁴ Another patient filled four alprazolam prescriptions from a single doctor over about three months, accumulating 166 excess tablets while filling opioid prescriptions at other pharmacies, and died ten days after picking up the last bottle.²

The complaint also points to prescriber red flags CVS allegedly ignored. In one instance, CVS continued filling hundreds of prescriptions for an Alabama doctor despite internal notes from 2015 flagging that he was under investigation; he was arrested in 2016. In another, CVS filled thousands of prescriptions for a Pennsylvania physician even after internal warnings and online patient reviews described him as a “pill pusher” who “writes scripts without seeing the patient.”³

The case began as a whistleblower complaint filed under the False Claims Act in October 2019 by former CVS employee Hillary Estright. The DOJ intervened on December 13, 2024, and the complaint was unsealed five days later.¹

The Staffing and Corporate Pressure Claims

A central thread in the DOJ’s complaint is that CVS’s corporate structure made careful dispensing impossible. The government alleges CVS imposed demanding performance metrics and incentive compensation programs that prioritized speed and volume, while setting staffing so low that pharmacists could not realistically verify every prescription they filled.¹

Internal CVS communications quoted in the complaint have pharmacists describing the environment as “soul crushing.” One employee compared the work to an assembly line, writing that “safety issues arise when one is dealing with medication and also being rushed to fulfill an order like McDonald’s.”³ The DOJ says CVS ignored repeated pharmacist complaints about dangerous understaffing and restricted pharmacists from sharing information with one another about suspicious prescribers.¹

The Legal Theory Behind the Case

At the heart of the lawsuit is the “corresponding responsibility” doctrine. Under 21 CFR §1306.04, prescriptions for controlled substances must be issued for a legitimate medical purpose by a practitioner acting within the usual course of professional practice. Pharmacists carry a parallel duty. They cannot simply fill whatever a doctor writes; they are legally obligated to evaluate prescriptions and refuse to dispense controlled substances when red flags suggest the prescription lacks a legitimate medical purpose.⁵

The DOJ characterizes pharmacies as the “final step in the pharmaceutical distribution process” and frames CVS’s alleged failures as an abdication of that gatekeeping role. Prosecutors argue that by filling suspicious prescriptions in bulk and then seeking reimbursement from federal programs like TRICARE, CVS crossed from regulatory noncompliance into federal fraud under the False Claims Act.¹

What makes this legal theory notable is that it bypasses the “public nuisance” framework that courts in Ohio and elsewhere have increasingly rejected in opioid cases. Instead of arguing broad community harm, the DOJ is putting each allegedly unlawful prescription in play as a separate false claim.

How CVS Is Defending Itself

CVS has vigorously contested the allegations. Spokesperson Kara Page called the lawsuit “misguided” and accused the government of promoting a “false narrative.” The company emphasizes that the prescriptions at issue were for FDA-approved medications written by doctors who were licensed and authorized by the government to prescribe controlled substances.⁶

A core element of CVS’s defense is that the legal standards the DOJ is trying to enforce do not actually exist in statute or regulation. CVS points to a 2019 letter from the DEA to the National Association of Chain Drug Stores acknowledging the agency lacks authority to issue guidelines that constitute medical advice and does not impose specific quantitative limits on controlled substance prescriptions. CVS also cites a 2006 Federal Register statement in which the DEA acknowledged it “cannot provide an exhaustive and foolproof list of ‘dos and don’ts'” for pharmacists handling controlled substances.⁶

The company also highlights internal compliance measures. CVS says it pioneered a program more than a decade ago that has blocked over 1,250 prescribers, including nearly 600 who remain government-licensed, from having prescriptions filled at its pharmacies. It says it uses algorithms to detect forged prescriptions, verifies prescribers’ active DEA registrations, provides safety alerts for high-dosage prescriptions, and gives pharmacists access to state prescription drug monitoring databases.⁶

CVS further argues that pharmacists face an impossible bind. They risk legal liability for filling questionable prescriptions and also face lawsuits when they refuse to fill legitimate ones, effectively second-guessing doctors’ medical judgments. CVS notes it has been sued by patients and advocates who argued its refusal policies went too far.⁶

On April 1, 2025, CVS filed a 45-page motion to dismiss most of the claims, arguing the complaint fails to show that the doctors behind more than 9,500 specific prescriptions actually acted unlawfully. Proving the underlying prescriptions were illegal, CVS contends, is an essential element the government has not adequately established.⁷

Where the Case Stands Now

As of mid-2026, the federal case remains in its early stages. On March 12, 2026, District Judge Melissa R. DuBose denied CVS’s motion to dismiss without prejudice, citing the parties’ repeated requests to postpone the hearing. The court’s order stated that after April 3, 2026, either party could ask to reopen the motion and schedule a new hearing date. No trial date or scheduling order has been set. The docket shows continued attorney appearances as recently as May 2026.⁸

What CVS Could Owe

The government is seeking civil penalties for each violation of the Controlled Substances Act and treble damages plus per-claim penalties under the False Claims Act. Per-claim penalties range from $5,500 to $23,607, with the higher figure applying to claims made after November 2015.² The DOJ is also seeking injunctive relief, which could require court-ordered changes to CVS’s corporate compliance programs.¹ No total exposure figure has been publicly disclosed.

For a rough sense of scale, Rite Aid settled similar False Claims Act and Controlled Substances Act allegations with the DOJ in July 2024 for roughly $408 million. That included a $7.5 million cash payment, a $401.8 million unsecured claim in Rite Aid’s bankruptcy proceedings, and a Corporate Integrity Agreement requiring ongoing government oversight.⁹ CVS operates far more pharmacies — over 9,000, compared to Rite Aid’s roughly 2,200 at the time of settlement.

The Separate $4.9 Billion State Settlement

The DOJ case is separate from an earlier CVS opioid resolution. In December 2022, CVS agreed to a $4.9 billion settlement with state and local governments over its role in the opioid crisis. The deal, which does not include any admission of wrongdoing, requires payments over ten years and covers participating states, local governments, and Native American tribes.¹⁰

Major states signed on before the end-of-2022 deadline, including New York, California, Pennsylvania, Oregon, Massachusetts, and North Carolina. New York was allocated approximately $458 million, California roughly $510 million, and Pennsylvania about $450 million.¹¹ Settlement funds are designated for opioid treatment, recovery, and prevention, and the agreement includes court-ordered monitoring of CVS’s business practices.¹² Payments began flowing in 2024 through court-appointed administrator BrownGreer.¹³ Signing on to that settlement did not resolve the federal claims now being pressed by the DOJ.

Other CVS Opioid Cases Still in Play

The federal case is running alongside other opioid litigation involving CVS, with mixed results for the company.

Ohio: Verdict Reversed

In November 2021, a federal jury in Cleveland found CVS, Walgreens, and Walmart liable for creating a public nuisance by failing to stop the flow of opioids into Lake and Trumbull counties. It was the first time retail pharmacies were held accountable by a jury for their role in the opioid crisis.¹⁴ U.S. District Judge Dan Aaron Polster ordered the three chains to pay $650.5 million in abatement costs over fifteen years.¹⁵

That judgment did not survive appeal. On December 10, 2024, the Ohio Supreme Court held that “all common-law public-nuisance claims arising from the sale of a product have been abrogated by the Ohio Product Liability Act.”¹⁶ Based on that ruling, the Sixth Circuit vacated the $650.5 million judgment and dissolved the injunction.¹⁷

Philadelphia: Case Moves Forward

Philadelphia sued CVS and other pharmacy defendants in 2021 under a public nuisance theory. On February 27, 2026, the Pennsylvania Superior Court affirmed the trial court’s denial of the pharmacies’ preliminary objections, ruling that Philadelphia had adequately alleged interference with a public right.¹⁸ Public nuisance is the sole surviving claim, and no trial date has been set.¹⁹

Florida: Directed Verdict for Pharmacies

A group of Florida hospitals sued CVS, Walgreens, and Walmart under state racketeering laws, seeking up to $1.5 billion for costs of treating opioid-affected patients. After a 51-day trial ended in a hung jury in late 2025, Broward County Circuit Court Judge Carol-Lisa Phillips granted a directed verdict for the pharmacies in May 2026, concluding the hospitals had suffered only indirect harm from treating patients rather than direct harm from the pharmacies’ conduct.²⁰²¹

The federal DOJ case sits apart from these state-level fights because it does not depend on a public nuisance theory. Its outcome will turn on whether the government can prove, prescription by prescription, that CVS knew the fills were unlawful and billed federal programs anyway. That question is likely to take years to resolve.

1
U.S. Department of Justice. Justice Department Files Nationwide Lawsuit Alleging CVS Knowingly Dispensed Controlled Substances
2
Rhode Island Current. DOJ Suit Claims CVS Ignored Red Flags, Dispensed Opioids From Dangerously Understaffed Pharmacies
3
CNN. DOJ Files Lawsuit Against CVS Over Opioid Dispensing
4
U.S. Department of Justice. DOJ Consolidated Complaint in Intervention
5
Journal of Ethics, American Medical Association. Pharmacist and Prescriber Responsibilities in Avoiding Prescription Drug Misuse
6
CVS Health. Our Opioid Response
7
Boston Globe. Opioid Lawsuit: CVS Argues Feds Did Not Provide Key Facts
8
CourtListener. United States of America v. CVS Health Corporation
9
HHS Office of Inspector General. Rite Aid Corporation and Affiliates Agree to Settle False Claims Act and Controlled Substance Act Allegations
10
Office of the Attorney General, North Carolina. AG Stein Announces $11B Opioid Settlement With CVS and Walgreens
11
NPR. CVS, Walgreens Opioid Crisis Settlement
12
New York Attorney General. Attorney General James Secures Over $10 Billion From CVS and Walgreens for Communities
13
KFF Health News. Opioid Settlement Payouts: State, County, City Tracker
14
Fierce Healthcare. Federal Jury Holds CVS, Walgreens, and Walmart Responsible for Role in Opioid Crisis
15
U.S. District Court, Northern District of Ohio. MDL 2804 National Prescription Opiate Litigation
16
Supreme Court of Ohio. In re National Prescription Opiate Litigation, 2024-Ohio-5744
17
U.S. Court of Appeals for the Sixth Circuit. In re National Prescription Opiate Litigation, Nos. 22-3750 et al.
18
Legal News Line. CVS Pharmacies Lose Bid to Toss Philadelphia’s Opioid Case
19
Superior Court of Pennsylvania. City of Philadelphia v. CVS RX Services, Superior Court Opinion
20
Reuters. CVS, Walgreens, Walmart Defeat Florida Hospitals’ Opioid Lawsuit
21
Daily Business Review. Judge Grants Directed Verdict for Pharmacies in Florida Opioid Trial